←
BioPartner UK3,125 posts
BioPartner UK avatar

BioPartner UK

@BioPartner

We are an independent, accredited trade organisation that supports UK international trade.

◷ Joined February 2009▧ 651 Photos and videos
BioPartner UK avatar
BioPartner UK@BioPartner·Jun 2

Thinking of attending Biospain? Why not get the most out of your experience by joining the UK Delegation?🇬🇧🇪🇸 Sign up here biopartner.co.uk/biospain Don’t miss your opportunity to be a part of the UK Guest Country Delegation at #BioSpain2026! Get your pass today.

Post attachmentPost attachmentPost attachment
Scendea avatar
⟳ BioPartner UK retweeted
Scendea@scendea·May 20

The EMA has updated a series of assessment timetable documents relating to initial marketing authorisation applications. Get in touch to discuss how the updated EMA timetables may affect your strategy: scendea.com/contact

Post attachmentPost attachmentPost attachmentPost attachment
Poolbeg Pharma avatar
⟳ BioPartner UK retweeted
Poolbeg Pharma@PoolbegPharma·May 20

Our Chief Executive Officer Jeremy Skillington & Chief Financial Officer Ian O'Connell will be attending @IAmBiotech Bio International Convention, one of the world’s leading events for the biotechnology and life sciences industry. 📍San Diego, US 🗓️22-25 June 2026 With interim data from the POLB 001 TOPICAL trial expected this summer, alongside the recent Canadian patent grant, momentum continues to build across the programme. The team looks forward to engaging with potential partners at BIO to discuss the clinical progress, our expanding IP portfolio, and broader commercial opportunity ahead. If you’re attending BIO 2026, connect with our team via the BIOpartnering platform. Learn more: convention.bio.org/ #POLB #BIO2026 #Biotech #LifeSciences #HealthcareInnovation #Biotechnology #Networking #Innovation #BIOInternational

Post attachment
Poolbeg Pharma avatar
⟳ BioPartner UK retweeted
Poolbeg Pharma@PoolbegPharma·Mar 12

To enhance our expertise in the Cytokine Release Syndrome space we have appointed Dr Adrian Kilcoyne to our Scientific Advisory Board. Dr Kilcoyne bring over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome. Adrian’s wealth of experience will provide further support to our established team of experts as we progress POLB 001 through the TOPICAL trial with the ultimate aim of transforming cancer care for patients and healthcare systems. Learn more about Dr Kilcoyne’s experience and read the full announcement here: londonstockexchange.com/news… #POLB #SAB #ScientificAdvisory #BoardMember #AIM #Cancer #Oncology #ScientificExpert

Post attachment